Sign in

You're signed outSign in or to get full access.

Faisal Khursheed

Senior Research Analyst at Jefferies

Faisal Khurshid is a Senior Research Analyst at Leerink Partners, leading coverage of the Emerging Immunology sector within biotechnology. He covers specific companies including Fusion Pharmaceuticals, Point Biopharma, Rain Oncology, AbCellera Biologics, Protagonist Therapeutics, Ironwood Pharmaceuticals, Spyre Therapeutics, Nurix Therapeutics, and Summit Therapeutics, with a notable call on Fusion Pharmaceuticals delivering approximately 900% returns from his November 2022 Outperform initiation before its acquisition by AstraZeneca. Khurshid issued 14 ratings over the last two years, primarily Buy recommendations (78.6%), and was honored as a 2024 Rising Star in Equity Research by Business Insider. He joined Leerink in 2021 after five years in biopharma consulting at ClearView Healthcare Partners and Axiom Healthcare Strategies, starting his career post-2016 graduation from Brown University with an Sc.B. in biomedical engineering.

Faisal Khursheed's questions to Summit Therapeutics (SMMT) leadership

Question · Q4 2025

Faisal Khursheed asked about any FDA interactions since the HARMONi BLA submission, specifically if the FDA's stance on the acceptability of PFS as a primary endpoint has changed, and the implications for HARMONi-3.

Answer

Dave Gancarz, Chief Business and Strategy Officer, confirmed ongoing confidential interactions with the FDA. He emphasized the company's respect for the agency and the importance of maintaining a strong relationship to advance Ivonescimab across multiple potential indications, declining to disclose specific meeting details.

Ask follow-up questions

Fintool

Fintool can predict Summit Therapeutics logo SMMT's earnings beat/miss a week before the call

Question · Q4 2025

Faisal Khursheed inquired about any interactions with the FDA since the HARMONi BLA submission and whether the FDA's stance on the acceptability of PFS, and its read-through to HARMONi-3, has changed.

Answer

Dave Gancarz, Chief Business and Strategy Officer, confirmed ongoing interactions with the FDA but stated that specific meeting discussions are confidential. He emphasized Summit's respect for the FDA's integrity and commitment to maintaining a strong relationship to advance ivonesimab for patients with unmet needs.

Ask follow-up questions

Fintool

Fintool can write a report on Summit Therapeutics logo SMMT's next earnings in your company's style and formatting